PR Distribution Report [011220176734037224681364000]

v.3.690


REPORT DETAILS
PR Distribution Report ID: 011220176734037224681364000
PR Distribution Campaign ID: 6734037224681364000
Customer: bill.weir@la-ser.com
Email for Contacts: swhite@accessibility-symposium.org
Press Release: 200 healthcare decision-makers gather to address the looming challenges of cost, access and sustainability in the coming wave of high-value medicines link opens in a new window
Press Release language: English
PR released on: Dec 1, 2017
Report started on: Dec 1, 2017
Report last updated on: Dec 11, 2017*

* Frequent updates on your PR distribution report are only done during the active period of your PR campaign. Further updates on this PR distribution report beyond the PR campaign period may be done on an irregular basis. You’ll be notified via an email if such an update has been made in future on your PR distribution report.
PR campaign duration:
The campaign duration depends on the PR distribution budget.
(Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
Is PR campaign active?
The active period of your PR distribution campaign depends on the PR distribution budget.
No. The active period of your PR distribution campaign is over*.

Extend PR campaign & reach?

* Even if the active period of your PR distribution campaign is over, your press release remains alive and is up and running on EuropaWire and all the places it has been published on, released via, submitted to and appeared on. The active period of your PR distribution campaign depends on the PR distribution budget and can be anything between one week and 30+ days if larger PR distribution budgets are used. During the active period of your PR distribution campaign, EuropaWire uses its news-wire platform and market insights to proactively engage in leveraging some of today’s most sophisticated and precise multi-channel targeting options available online to source and reach out to the audience that might be interested in and engage with your PR message based on your targeting preferences. The larger the PR distribution budget the longer both the PR distribution campaign and the observed period covered by your PR distribution report.
PR report observed period:
The observed period for the PR distribution report depends on the PR distribution campaign duration.
(Dec 1, 2017 – Dec 11, 2017 ~ 11 days)*

*The observed period for the PR distribution report is tied up with the PR distribution budget used and covers the active period of your PR distribution campaign. The larger the PR distribution budget the longer both the PR distribution campaign and the observed period covered by your PR distribution report.
Report in progress: No
Report is completed: Yes
PR distribution budget for Germany (EU): €99
PR distribution budget for France (EU): €99
PR distribution budget for United Kingdom (EU): €299
PR distribution budget (total): €497
Total reach: 225,491+ (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
Reach level:
Indicates how optimal your reach is versus the average for the PR distribution budget employed.
Reach level~41%*

* Please note that while this indicator looks into how your reach performed towards the average for the same PR budget, targeting different countries, markets and audiences usually results in significantly different reach level for PR distribution campaigns with the same PR budgets.
TABLE OF CONTENT
1) Where did we publish on, release via and submit to…
2) Who did we target, where and how…
3) Who did we reach out to…
4) Who engaged…
5) Insights…
6) Extend…
WHERE DID WE PUBLISH…
Your press release has been published on, released via, submitted to, and appeared on EuropaWire, the Internet, Web, Search engines, the Blogosphere, News, News aggregators, Social media, etc.
Site URL
EuropaWire: Press release page:

https://news.europawire.eu/200-healthcare-decision-makers-gather-to-address-the-looming-challenges-of-cost-access-and-sustainability-in-the-coming-wave-of-high-value-medicines-64000/eu-press-release/2017/12/01/

Categories:

https://news.europawire.eu/government/
https://news.europawire.eu/healthcare/
https://news.europawire.eu/news/
https://news.europawire.eu/non-profit/
https://news.europawire.eu/pharma-biotech/
https://news.europawire.eu/science/
https://news.europawire.eu/society/
https://news.europawire.eu/united-kingdom/

Tags:

https://news.europawire.eu/press-releases-tagged-with/academia/
https://news.europawire.eu/press-releases-tagged-with/aetna/
https://news.europawire.eu/press-releases-tagged-with/analyticalaser/
https://news.europawire.eu/press-releases-tagged-with/auto-immune-diseases/
https://news.europawire.eu/press-releases-tagged-with/biopharmaceutical/
https://news.europawire.eu/press-releases-tagged-with/biopharmaceutical-developers/
https://news.europawire.eu/press-releases-tagged-with/cancer/
https://news.europawire.eu/press-releases-tagged-with/deadly-hiv-epidemic/
https://news.europawire.eu/press-releases-tagged-with/dr-harold-paz/
https://news.europawire.eu/press-releases-tagged-with/dr-olivier-brandicourt/
https://news.europawire.eu/press-releases-tagged-with/dr-sarah-garner/
https://news.europawire.eu/press-releases-tagged-with/drug-developers/
https://news.europawire.eu/press-releases-tagged-with/drug-policy/
https://news.europawire.eu/press-releases-tagged-with/eurordis-rare-diseases-europe/
https://news.europawire.eu/press-releases-tagged-with/french-has/
https://news.europawire.eu/press-releases-tagged-with/global-health-systems-sustainability/
https://news.europawire.eu/press-releases-tagged-with/government/
https://news.europawire.eu/press-releases-tagged-with/health-ministries/
https://news.europawire.eu/press-releases-tagged-with/health-systems/
https://news.europawire.eu/press-releases-tagged-with/healthcare/
https://news.europawire.eu/press-releases-tagged-with/high-cost-medical-therapies/
https://news.europawire.eu/press-releases-tagged-with/high-value-medicines/
https://news.europawire.eu/press-releases-tagged-with/julia-corner/
https://news.europawire.eu/press-releases-tagged-with/life-saving-drugs/
https://news.europawire.eu/press-releases-tagged-with/london-school-of-hygiene-and-tropical-medicine/
https://news.europawire.eu/press-releases-tagged-with/medicine-access/
https://news.europawire.eu/press-releases-tagged-with/medicine-accessibility/
https://news.europawire.eu/press-releases-tagged-with/national-institute-for-health-and-care-excellence/
https://news.europawire.eu/press-releases-tagged-with/not-for-profit-event/
https://news.europawire.eu/press-releases-tagged-with/patient-access/
https://news.europawire.eu/press-releases-tagged-with/patient-organisations/
https://news.europawire.eu/press-releases-tagged-with/pharmaceutical/
https://news.europawire.eu/press-releases-tagged-with/prof-peter-piot/
https://news.europawire.eu/press-releases-tagged-with/prof-dominique-le-guludec/
https://news.europawire.eu/press-releases-tagged-with/prof-lucien-abenhaim/
https://news.europawire.eu/press-releases-tagged-with/rare-disease/
https://news.europawire.eu/press-releases-tagged-with/rare-diseases/
https://news.europawire.eu/press-releases-tagged-with/renaissance-st-pancras-hotel/
https://news.europawire.eu/press-releases-tagged-with/sanofi/
https://news.europawire.eu/press-releases-tagged-with/sir-andrew-dillon/
https://news.europawire.eu/press-releases-tagged-with/ulrich-neumann/
https://news.europawire.eu/press-releases-tagged-with/world-health-organization/
https://news.europawire.eu/press-releases-tagged-with/yann-le-cam/

Google: https://www.google.com/search?hl=en&noj=1
Google News: https://www.google.com/search?q=
Bing News: https://www.bing.com/news/search?q=…
Apple News:
(To view this channel open the link on an iPad, iPhone, or iPod touch with iOS 9 or later and Apple News)
https://apple.news/TgIdasElxRICK2SON_8eNPw
Yahoo Search: http://search.yahoo.com/search?…
Bing Search: http://www.bing.com/search?…
Blogosphere: http://www.blogsearchengine.org/search.html?cx=
Twitter: https://twitter.com/europawire

https://twitter.com/europawire/status/936596636800835584
https://twitter.com/hashtag/healthcare?src=hash
https://twitter.com/hashtag/medicines?src=hash
https://t.co/M8ArBmbQDt
https://twitter.com/hashtag/healthcare?src=hash
https://twitter.com/hashtag/medicineaccess?src=hash
https://twitter.com/hashtag/medicineaccessibility?src=hash
https://twitter.com/hashtag/highvaluemedicines?src=hash
https://twitter.com/hashtag/lifesavingdrugs?src=hash
https://twitter.com/hashtag/raredisease?src=hash
https://t.co/BElpOoDalO
https://twitter.com/search?q=place%3A457b4814b4240d87
https://twitter.com/PemphigusVulgar
https://twitter.com/eprnetwork
https://twitter.com/europawire
https://twitter.com/LSHTMpress
https://twitter.com/analytica_laser
https://twitter.com/WHO
https://twitter.com/LSHTMpress
https://twitter.com/analytica_laser
https://twitter.com/WHO
https://twitter.com/eurordis
https://twitter.com/yann_eurordis
https://twitter.com/drsarahgarner
https://twitter.com/drhpaz
https://twitter.com/StPancrasRen

https://twitter.com/europawire/status/936655519326048258
https://t.co/M8ArBmbQDt
https://twitter.com/hashtag/healthcare?src=hash
https://twitter.com/hashtag/medicines?src=hash
https://twitter.com/hashtag/medicineaccess?src=hash
https://twitter.com/hashtag/medicineaccessibility?src=hash
https://twitter.com/hashtag/highvaluemedicines?src=hash
https://twitter.com/hashtag/lifesavingdrugs?src=hash
https://twitter.com/hashtag/raredisease?src=hash
https://twitter.com/hashtag/drugpolicy?src=hash
https://twitter.com/hashtag/biopharmaceutical?src=hash
https://twitter.com/hashtag/pharmaceutical?src=hash
https://t.co/MiVTJ0tkxI
https://twitter.com/search?q=place%3A457b4814b4240d87
https://twitter.com/Proqy0
https://twitter.com/PemphigusVulgar
https://twitter.com/eprnetwork
https://twitter.com/europawire
https://twitter.com/LSHTMpress
https://twitter.com/analytica_laser
https://twitter.com/eurordis
https://twitter.com/LSHTMpress
https://twitter.com/analytica_laser
https://twitter.com/eurordis
https://twitter.com/drsarahgarner
https://twitter.com/drhpaz
https://twitter.com/PHE_uk
https://twitter.com/NHSEngland

https://twitter.com/europawire/status/936656848979193857
https://t.co/M8ArBmbQDt
https://twitter.com/hashtag/healthcare?src=hash
https://twitter.com/hashtag/medicines?src=hash
https://twitter.com/hashtag/medicineaccess?src=hash
https://twitter.com/hashtag/medicineaccessibility?src=hash
https://twitter.com/hashtag/highvaluemedicines?src=hash
https://twitter.com/hashtag/raredisease?src=hash
https://t.co/aHg67WJDCd
https://twitter.com/search?q=place%3A457b4814b4240d87
https://twitter.com/eprnetwork
https://twitter.com/europawire
https://twitter.com/analytica_laser
https://twitter.com/LSHTMpress
https://twitter.com/eurordis
https://twitter.com/analytica_laser
https://twitter.com/LSHTMpress
https://twitter.com/eurordis
https://twitter.com/PharmaTimes
https://twitter.com/Pharmafocus
https://twitter.com/PharmExec

https://twitter.com/europawire/status/936659825865515008
https://twitter.com/hashtag/patient?src=hash
https://twitter.com/hashtag/medical?src=hash
https://twitter.com/hashtag/therapies?src=hash
https://t.co/M8ArBmbQDt
https://twitter.com/hashtag/raredisease?src=hash
https://twitter.com/hashtag/drugpolicy?src=hash
https://twitter.com/hashtag/biopharmaceutical?src=hash
https://twitter.com/hashtag/pharmaceutical?src=hash
https://twitter.com/hashtag/healthsystems?src=hash
https://twitter.com/hashtag/drugdevelopers?src=hash
https://t.co/Y4aqJvMv0c
https://twitter.com/search?q=place%3A457b4814b4240d87
https://twitter.com/TalibSh52444470
https://twitter.com/Antonycorreia78
https://twitter.com/margaux_viguie
https://twitter.com/Lolz1975Tilly
https://twitter.com/TheSamOff
https://twitter.com/H_S_Global
https://twitter.com/_DarkVa_dehors
https://twitter.com/ViolettaBomba
https://twitter.com/PemphigusVulgar
https://twitter.com/analytica_laser
https://twitter.com/LSHTMpress
https://twitter.com/yann_eurordis
https://twitter.com/analytica_laser
https://twitter.com/LSHTMpress
https://twitter.com/yann_eurordis
https://twitter.com/drsarahgarner
https://twitter.com/drhpaz
https://twitter.com/pharmaphorum
https://twitter.com/eyeforpharma
https://twitter.com/pharmanewseu

https://twitter.com/europawire/status/936667975062577152
https://t.co/M8ArBmbQDt
https://twitter.com/hashtag/healthcare?src=hash
https://twitter.com/hashtag/medicines?src=hash
https://twitter.com/hashtag/medicineaccess?src=hash
https://twitter.com/hashtag/medicineaccessibility?src=hash
https://twitter.com/hashtag/highvaluemedicines?src=hash
https://twitter.com/hashtag/lifesavingdrugs?src=hash
https://twitter.com/hashtag/raredisease?src=hash
https://twitter.com/hashtag/drugpolicy?src=hash
https://twitter.com/hashtag/biopharmaceutical?src=hash
https://t.co/XpON4KCSaC
https://twitter.com/search?q=place%3A457b4814b4240d87
https://twitter.com/eprnetwork
https://twitter.com/europawire
https://twitter.com/RobertCraigRig2
https://twitter.com/LSHTMpress
https://twitter.com/analytica_laser
https://twitter.com/WHO
https://twitter.com/LSHTMpress
https://twitter.com/analytica_laser
https://twitter.com/WHO
https://twitter.com/eurordis
https://twitter.com/ehealthnews
https://twitter.com/EU_eHealth
https://twitter.com/leQPH_fr
https://twitter.com/PharmaTimes

https://twitter.com/europawire/status/936670495084249089
https://twitter.com/hashtag/HIV?src=hash
https://twitter.com/hashtag/epidemic?src=hash
https://twitter.com/hashtag/accessibility?src=hash
https://twitter.com/hashtag/medicine?src=hash
https://twitter.com/hashtag/cancer?src=hash
https://twitter.com/hashtag/autoimmunediseases?src=hash
https://twitter.com/hashtag/rarediseases?src=hash
https://t.co/M8ArBmbQDt
https://t.co/xab8aov7jg
https://twitter.com/search?q=place%3A457b4814b4240d87
https://twitter.com/Proqy0
https://twitter.com/eprnetwork
https://twitter.com/europawire
https://twitter.com/analytica_laser
https://twitter.com/LSHTMpress
https://twitter.com/moniteur_news
https://twitter.com/analytica_laser
https://twitter.com/LSHTMpress
https://twitter.com/moniteur_news
https://twitter.com/PharmaciendeF
https://twitter.com/PharmExec
https://twitter.com/eyeforpharma

https://twitter.com/europawire/status/936674005364477952
https://twitter.com/hashtag/raredisease?src=hash
https://twitter.com/hashtag/medicine?src=hash
https://t.co/M8ArBmbQDt
https://twitter.com/hashtag/medicineaccess?src=hash
https://twitter.com/hashtag/medicineaccessibility?src=hash
https://twitter.com/hashtag/highvaluemedicines?src=hash
https://twitter.com/hashtag/lifesavingdrugs?src=hash
https://twitter.com/hashtag/raredisease?src=hash
https://twitter.com/hashtag/drugpolicy?src=hash
https://twitter.com/eurordis
https://t.co/l2fPX8NW7B
https://twitter.com/search?q=place%3A457b4814b4240d87
https://twitter.com/eprnetwork
https://twitter.com/europawire
https://twitter.com/LSHTMpress
https://twitter.com/analytica_laser
https://twitter.com/yann_eurordis
https://twitter.com/LSHTMpress
https://twitter.com/analytica_laser
https://twitter.com/yann_eurordis
https://twitter.com/drsarahgarner
https://twitter.com/drhpaz
https://twitter.com/bionity_com
https://twitter.com/bionity_de
https://twitter.com/biotechnologie
https://twitter.com/BIODeutschland
https://twitter.com/EuropaBio

https://twitter.com/europawire/status/936677418642833408
https://t.co/M8ArBmbQDt
https://twitter.com/hashtag/medicineaccess?src=hash
https://twitter.com/hashtag/medicineaccessibility?src=hash
https://twitter.com/hashtag/highvaluemedicines?src=hash
https://twitter.com/hashtag/lifesavingdrugs?src=hash
https://twitter.com/hashtag/raredisease?src=hash
https://t.co/dWFCN39JaX
https://twitter.com/search?q=place%3A457b4814b4240d87
https://twitter.com/Peter__Lawler
https://twitter.com/eprnetwork
https://twitter.com/europawire
https://twitter.com/cimbomcakal
https://twitter.com/LSHTMpress
https://twitter.com/analytica_laser
https://twitter.com/eurordis
https://twitter.com/LSHTMpress
https://twitter.com/analytica_laser
https://twitter.com/eurordis
https://twitter.com/drsarahgarner
https://twitter.com/drhpaz
https://twitter.com/StPancrasRen
https://twitter.com/pharmafakten
https://twitter.com/pharmazeitung
https://twitter.com/eyeforpharma
https://twitter.com/PharmaTimes

https://twitter.com/eprnetwork/status/937289546349281280
https://twitter.com/hashtag/HEALTH?src=hash
https://t.co/fmq7BK6yui
https://twitter.com/hashtag/healthcare?src=hash
https://twitter.com/hashtag/medicines?src=hash
https://twitter.com/hashtag/medicineaccess?src=hash
https://twitter.com/hashtag/medicineaccessibility?src=hash
https://twitter.com/hashtag/highvaluemedicines?src=hash
https://twitter.com/hashtag/lifesavingdrugs?src=hash
https://twitter.com/hashtag/raredisease?src=hash
https://twitter.com/hashtag/drugpolicy?src=hash

https://twitter.com/eprnetwork/status/937290104258940928
https://twitter.com/hashtag/SYMPOSIUM?src=hash
https://twitter.com/hashtag/MEDICINE?src=hash
https://t.co/7xPVgbDE9I
https://twitter.com/hashtag/medicineaccess?src=hash
https://twitter.com/hashtag/medicineaccessibility?src=hash
https://twitter.com/hashtag/highvaluemedicines?src=hash
https://twitter.com/hashtag/lifesavingdrugs?src=hash
https://twitter.com/hashtag/raredisease?src=hash
https://twitter.com/hashtag/drugpolicy?src=hash
https://twitter.com/hashtag/biopharmaceutical?src=hash
https://twitter.com/hashtag/pharmaceutical?src=hash

Facebook: https://www.facebook.com/EuropaWire

https://www.facebook.com/EuropaWire/posts/1262002963945159
https://www.facebook.com/hashtag/healthcare?source=feed_text&story_id=1262002963945159
https://www.facebook.com/hashtag/medicines?source=feed_text&story_id=1262002963945159
https://www.facebook.com/hashtag/medicineaccess?source=feed_text&story_id=1262002963945159
https://www.facebook.com/hashtag/medicineaccessibility?source=feed_text&story_id=1262002963945159
https://www.facebook.com/hashtag/highvaluemedicines?source=feed_text&story_id=1262002963945159
https://www.facebook.com/hashtag/lifesavingdrugs?source=feed_text&story_id=1262002963945159
https://www.facebook.com/hashtag/raredisease?source=feed_text&story_id=1262002963945159
https://www.facebook.com/hashtag/drugpolicy?source=feed_text&story_id=1262002963945159
https://www.facebook.com/hashtag/biopharmaceutical?source=feed_text&story_id=1262002963945159
https://www.facebook.com/hashtag/pharmaceutical?source=feed_text&story_id=1262002963945159
https://www.facebook.com/hashtag/healthsystems?source=feed_text&story_id=1262002963945159
https://www.facebook.com/hashtag/drugdevelopers?source=feed_text&story_id=1262002963945159
https://www.facebook.com/london.school.hygiene.tropical.medicine/?fref=mentions
https://www.facebook.com/WHO/?fref=mentions
https://www.facebook.com/eurordis/?fref=mentions
https://www.facebook.com/stpancrasren/?fref=mentions
https://www.facebook.com/pages/Sally-Davies-professor/143735782307072?fref=mentions
https://www.facebook.com/PublicHealthEngland/?fref=mentions
https://www.facebook.com/Pharmafocusuk/?fref=mentions
https://www.facebook.com/pharmaphorum/?fref=mentions
https://www.facebook.com/eyeforpharma/?fref=mentions
https://www.facebook.com/EuropaWire/photos/a.450468198431977.1073741825.149517881860345/1262001340611988/?type=3

https://www.facebook.com/hashtag/healthcare?source=feed_text&story_id=1262026453942810
https://www.facebook.com/hashtag/medicines?source=feed_text&story_id=1262026453942810
https://www.facebook.com/hashtag/medicineaccess?source=feed_text&story_id=1262026453942810
https://www.facebook.com/hashtag/medicineaccessibility?source=feed_text&story_id=1262026453942810
https://www.facebook.com/hashtag/highvaluemedicines?source=feed_text&story_id=1262026453942810
https://www.facebook.com/hashtag/lifesavingdrugs?source=feed_text&story_id=1262026453942810
https://www.facebook.com/hashtag/raredisease?source=feed_text&story_id=1262026453942810
https://www.facebook.com/hashtag/drugpolicy?source=feed_text&story_id=1262026453942810
https://www.facebook.com/hashtag/biopharmaceutical?source=feed_text&story_id=1262026453942810
https://www.facebook.com/hashtag/pharmaceutical?source=feed_text&story_id=1262026453942810
https://www.facebook.com/hashtag/healthsystems?source=feed_text&story_id=1262026453942810
https://www.facebook.com/hashtag/drugdevelopers?source=feed_text&story_id=1262026453942810
https://www.facebook.com/london.school.hygiene.tropical.medicine/?fref=mentions
https://www.facebook.com/WHO/?fref=mentions
https://www.facebook.com/eurordis/?fref=mentions
https://www.facebook.com/stpancrasren/?fref=mentions
https://www.facebook.com/RareDiseaseUK/?fref=mentions
https://www.facebook.com/EU.eHealth/?fref=mentions
https://www.facebook.com/moniteur.pharmacies/?fref=mentions
https://www.facebook.com/EuropaBio/?fref=mentions
https://www.facebook.com/pharmazeitung/?fref=mentions
https://www.facebook.com/EuropaWire/photos/a.450468198431977.1073741825.149517881860345/1262024127276376/?type=3

https://www.facebook.com/EuropaWire/posts/1262063363939119
https://www.facebook.com/hashtag/healthcare?source=feed_text&story_id=1262063363939119
https://www.facebook.com/hashtag/medicines?source=feed_text&story_id=1262063363939119
https://www.facebook.com/hashtag/medicineaccess?source=feed_text&story_id=1262063363939119
https://www.facebook.com/hashtag/medicineaccessibility?source=feed_text&story_id=1262063363939119
https://www.facebook.com/hashtag/highvaluemedicines?source=feed_text&story_id=1262063363939119
https://www.facebook.com/hashtag/lifesavingdrugs?source=feed_text&story_id=1262063363939119
https://www.facebook.com/hashtag/raredisease?source=feed_text&story_id=1262063363939119
https://www.facebook.com/hashtag/drugpolicy?source=feed_text&story_id=1262063363939119
https://www.facebook.com/hashtag/biopharmaceutical?source=feed_text&story_id=1262063363939119
https://www.facebook.com/hashtag/pharmaceutical?source=feed_text&story_id=1262063363939119
https://www.facebook.com/hashtag/healthsystems?source=feed_text&story_id=1262063363939119
https://www.facebook.com/hashtag/drugdevelopers?source=feed_text&story_id=1262063363939119
https://www.facebook.com/london.school.hygiene.tropical.medicine/?fref=mentions
https://www.facebook.com/WHO/?fref=mentions
https://www.facebook.com/eurordis/?fref=mentions
https://www.facebook.com/stpancrasren/?fref=mentions
https://www.facebook.com/RareDiseaseUK/?fref=mentions
https://www.facebook.com/EuropaWire/photos/pcb.1262063363939119/1262054643939991/?type=3
https://www.facebook.com/EuropaWire/photos/pcb.1262063363939119/1262054410606681/?type=3
https://www.facebook.com/EuropaWire/photos/pcb.1262063363939119/1262056257273163/?type=3
https://www.facebook.com/EuropaWire/photos/pcb.1262063363939119/1262056283939827/?type=3

Instagram: N/A
G+ https://plus.google.com/+EuropaWire

https://plus.google.com/+EuropaWire/posts/iX1qbpi9R8q
https://plus.google.com//s/%23healthcare/posts
https://plus.google.com//s/%23medicines/posts
https://plus.google.com//s/%23medicineaccess/posts
https://plus.google.com//s/%23medicineaccessibility/posts
https://plus.google.com//s/%23highvaluemedicines/posts
https://plus.google.com//s/%23lifesavingdrugs/posts
https://plus.google.com//s/%23raredisease/posts
https://plus.google.com//s/%23drugpolicy/posts
https://plus.google.com//s/%23biopharmaceutical/posts
https://plus.google.com//s/%23pharmaceutical/posts
https://plus.google.com//s/%23healthsystems/posts
https://plus.google.com//s/%23drugdevelopers/posts
https://plus.google.com//114558863704884037004
https://plus.google.com//114387522754314829925
https://plus.google.com//100313689108396962032
https://plus.google.com//108287522491692925357
https://plus.google.com//110217196289219881658
https://plus.google.com//116967773245672588203
https://plus.google.com//116780466707114440569
https://plus.google.com//114128949154544800496
https://plus.google.com//115130963956812667310

https://plus.google.com/+EuropaWire/posts/M26gAH9aQ8L
https://plus.google.com//s/%23healthcare/posts
https://plus.google.com//s/%23medicines/posts
https://plus.google.com//s/%23medicineaccess/posts
https://plus.google.com//s/%23medicineaccessibility/posts
https://plus.google.com//s/%23highvaluemedicines/posts
https://plus.google.com//s/%23lifesavingdrugs/posts
https://plus.google.com//s/%23raredisease/posts
https://plus.google.com//s/%23drugpolicy/posts
https://plus.google.com//s/%23biopharmaceutical/posts
https://plus.google.com//s/%23pharmaceutical/posts
https://plus.google.com//s/%23healthsystems/posts
https://plus.google.com//s/%23drugdevelopers/posts
https://plus.google.com//114558863704884037004
https://plus.google.com//114387522754314829925
https://plus.google.com//116780466707114440569
https://plus.google.com//113957786601725889031
https://plus.google.com//113385891504870058110
https://plus.google.com//104344261673137893275

https://plus.google.com/+EuropaWire/posts/TBfjvYg59CY
https://plus.google.com//s/%23healthcare/posts
https://plus.google.com//s/%23medicines/posts
https://plus.google.com//s/%23medicineaccess/posts
https://plus.google.com//s/%23medicineaccessibility/posts
https://plus.google.com//s/%23highvaluemedicines/posts
https://plus.google.com//s/%23lifesavingdrugs/posts
https://plus.google.com//s/%23raredisease/posts
https://plus.google.com//s/%23drugpolicy/posts
https://plus.google.com//s/%23biopharmaceutical/posts
https://plus.google.com//s/%23pharmaceutical/posts
https://plus.google.com//s/%23healthsystems/posts
https://plus.google.com//s/%23drugdevelopers/posts
https://plus.google.com//114558863704884037004
https://plus.google.com//114387522754314829925
https://plus.google.com//100313689108396962032
https://plus.google.com//116780466707114440569
https://plus.google.com//104952447379099626466

Pinterest: https://www.pinterest.com/europawire

https://www.pinterest.com/europawire/healthcare/
https://www.pinterest.com/europawire/pharma-biotech/
https://www.pinterest.com/europawire/non-profit/
https://www.pinterest.com/europawire/society/
https://www.pinterest.com/europawire/education/
https://www.pinterest.com/europawire/marketing/
https://www.pinterest.com/europawire/science/
https://www.pinterest.com/pin/399413060695432390/
https://www.pinterest.com/pin/399413060695432392/
https://www.pinterest.com/pin/399413060695432394/
https://www.pinterest.com/pin/399413060695432400/
https://www.pinterest.com/pin/399413060695432415/
https://www.pinterest.com/pin/399413060695432420/
https://www.pinterest.com/pin/399413060695432422/
https://www.pinterest.com/pin/399413060695432425/
https://www.pinterest.com/pin/399413060695432436/
https://www.pinterest.com/pin/399413060695432433/
https://www.pinterest.com/pin/399413060695432430/
https://www.pinterest.com/pin/399413060695432444/
https://www.pinterest.com/pin/399413060695432447/
https://www.pinterest.com/pin/399413060695432450/
https://www.pinterest.com/pin/399413060695432445/

Flipboard: https://flipboard.com/@europawire

https://flipboard.com/@europawire/healthcare-vkgkndpcy
https://flipboard.com/@europawire/pharma-%26-biotech-t3albt3dy
https://flipboard.com/@europawire/society-g6ovoh9cy
https://flipboard.com/@europawire/science-0tcm80agy
https://flipboard.com/@europawire/non-profit-4j3auo1iy

crunchbase:

https://www.crunchbase.com/organization/world-health-organization
https://www.crunchbase.com/organization/london-school-of-hygiene-tropical-medicine
https://www.crunchbase.com/organization/eurordis-rare-diseases-europe
https://www.crunchbase.com/organization/sanofi
https://www.crunchbase.com/organization/national-institute-for-health-and-care-excellence-nice
https://www.crunchbase.com/organization/aetna

Paper.li: https://paper.li/e-1431004197
EPR Healthcare News:

https://www.eprhealthcarenews.com/2017/12/03/3897-prof-lucien-abenhaim-there-is-an-incredible-challenge-for-the-sustainability-of-health-systems-across-the-world/
https://www.eprhealthcarenews.com/category/business-of-medicine/
https://www.eprhealthcarenews.com/category/cancer/
https://www.eprhealthcarenews.com/category/critical-care/
https://www.eprhealthcarenews.com/category/diseases/
https://www.eprhealthcarenews.com/category/doctors/
https://www.eprhealthcarenews.com/category/drugs/
https://www.eprhealthcarenews.com/category/emergency-medicine/
https://www.eprhealthcarenews.com/category/health-plans/
https://www.eprhealthcarenews.com/category/health-reform/
https://www.eprhealthcarenews.com/category/healthcare/
https://www.eprhealthcarenews.com/category/healthcare-professionals/
https://www.eprhealthcarenews.com/category/medicine/
https://www.eprhealthcarenews.com/category/oncology/
https://www.eprhealthcarenews.com/category/pharmaceuticals/
https://www.eprhealthcarenews.com/category/public-health/
https://www.eprhealthcarenews.com/category/regulation/
https://www.eprhealthcarenews.com/category/society/
https://www.eprhealthcarenews.com/category/therapies/
https://www.eprhealthcarenews.com/tag/biopharmaceutical/
https://www.eprhealthcarenews.com/tag/drug-developers/
https://www.eprhealthcarenews.com/tag/drug-policy/
https://www.eprhealthcarenews.com/tag/health-systems/
https://www.eprhealthcarenews.com/tag/healthcare/
https://www.eprhealthcarenews.com/tag/high-cost-medical-therapies/
https://www.eprhealthcarenews.com/tag/high-value-medicines/
https://www.eprhealthcarenews.com/tag/life-saving-drugs/
https://www.eprhealthcarenews.com/tag/lucien-abenhaim/
https://www.eprhealthcarenews.com/tag/medicine-access/
https://www.eprhealthcarenews.com/tag/medicine-accessibility/
https://www.eprhealthcarenews.com/tag/pharmaceutical/
https://www.eprhealthcarenews.com/tag/prof-lucien-abenhaim/
https://www.eprhealthcarenews.com/tag/rare-disease/

EPR Biotech News:

https://www.eprbiotechnews.com/2017/12/03/10630-international-symposium-on-the-accessibility-to-high-value-medicine-december-5-6-2017-in-london/
https://www.eprbiotechnews.com/category/biopharmaceutical/
https://www.eprbiotechnews.com/category/biotech/
https://www.eprbiotechnews.com/category/healthcare/
https://www.eprbiotechnews.com/category/law/
https://www.eprbiotechnews.com/category/licenses/
https://www.eprbiotechnews.com/category/medicine/
https://www.eprbiotechnews.com/category/pharmaceuticals/
https://www.eprbiotechnews.com/category/policy/
https://www.eprbiotechnews.com/category/regulations/
https://www.eprbiotechnews.com/category/vaccines/
https://www.eprbiotechnews.com/tag/accessibility-to-high-value-medicine/
https://www.eprbiotechnews.com/tag/analyticalaser/
https://www.eprbiotechnews.com/tag/auto-immune-diseases/
https://www.eprbiotechnews.com/tag/biopharmaceutical-developers/
https://www.eprbiotechnews.com/tag/cancer/
https://www.eprbiotechnews.com/tag/drug-policy/
https://www.eprbiotechnews.com/tag/high-cost-medical-therapies/
https://www.eprbiotechnews.com/tag/high-value-medicine/
https://www.eprbiotechnews.com/tag/life-saving-drugs/
https://www.eprbiotechnews.com/tag/london-school-of-hygiene-and-tropical-medicine/
https://www.eprbiotechnews.com/tag/rare-diseases/

WHO DID WE TARGET…
Countries, markets, verticals, audiences, interests, industries, categories, keywords, tags, etc.
Countries: Germany (EU)
France (EU)
United Kingdom (EU)
Language: English
Regions, Metros, DMAs, Cities, Towns, etc.: N/A
Industries: Healthcare, Pharma & Biotech, Science, Government, Non Profit, Society, etc.
Markets / Verticals: high-value medicines, drug policy, medicine access, etc.
Audiences: Internet, search engines and social media users living/residing in Germany (EU), France (EU), United Kingdom (EU) using English language and with identified interests like Healthcare, Pharma & Biotech, Science, Government, Non Profit, Society, biopharmaceutical, pharmaceutical, high-value medicines, drug policy, medicine access, healthcare, life-saving drugs, medicine accessibility, health systems, drug developers, rare disease, etc.
Age: 18-65
Gender: All
Interests: Healthcare, Pharma & Biotech, Science, Government, Non Profit, Society, biopharmaceutical, pharmaceutical, high-value medicines, drug policy, medicine access, healthcare, life-saving drugs, medicine accessibility, health systems, drug developers, rare disease, etc.
Categories, Keywords, Tags: Healthcare, Pharma & Biotech, Science, Government, Non Profit, Society, academia, Aetna, analytica|LASER, auto-immune diseases, biopharmaceutical, biopharmaceutical developers, Cancer, deadly HIV epidemic, Dr. Harold Paz, Dr. Olivier Brandicourt, Dr. Sarah Garner, drug developers, drug policy, EURORDIS-Rare Diseases Europe, French HAS, global health systems sustainability, government, health ministries, health systems, Healthcare, high-cost medical therapies, high-value medicines, Julia Corner, life-saving drugs, London School of Hygiene and Tropical Medicine, medicine access, medicine accessibility, National Institute for Health and Care Excellence, not-for-profit event, patient access, patient organisations, Pharmaceutical, Prof Peter Piot, Prof. Dominique Le Guludec, Prof. Lucien Abenhaim, rare disease, rare diseases, Renaissance St Pancras Hotel, Sanofi, Sir Andrew Dillon, Ulrich Neumann, World Health Organization, Yann Le Cam, etc.
Platforms: Desktop, mobile
WHO DID WE REACH OUT TO…
Total targeted reach, social media reach, followers, subscribers, etc.
Total generic reach: 27,290 people (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
Total generic video views: 0 people (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
Total targeted reach: 198,201 people (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
Total targeted video views: 0 people (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
–Cost per PR targeted reach: €0.0025
–Cost per PR targeted video view: €0.00
In Germany (EU):
–Total targeted reach: 44,341 people (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
–Total targeted video views: 0 people (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
—-Cost per PR targeted reach: €0.0022
—-Cost per PR targeted video view: €0.00
In France (EU):
–Total targeted reach: 31,101 people (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
–Total targeted video views: 0 people (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
—-Cost per PR targeted reach: €0.0031
—-Cost per PR targeted video view: €0.00
In United Kingdom (EU):
–Total targeted reach: 122,759 people (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
–Total targeted video views: 0 people (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
—-Cost per PR targeted reach: €0.0024
—-Cost per PR targeted video view: €0.00
Total reach:
(generic + targeted)
225,491 people (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
Cost per PR total reach: €0.0022
Who did we reach: 198,201+ internet, search engines and social media users living/residing in Germany (EU), France (EU), United Kingdom (EU) using English language and with identified interests like Healthcare, Pharma & Biotech, Science, Government, Non Profit, Society, biopharmaceutical, pharmaceutical, high-value medicines, drug policy, medicine access, healthcare, life-saving drugs, medicine accessibility, health systems, drug developers, rare disease, etc.
Combined number of followers the PR reached out to:
(Twitter, FB, G+, incl. re-tweets, likes, shares, etc.)
33,932+
Cost per follower reach: €0.014
High profile European influencers reached: 200+

(European/EU politicians, policy makers, government leaders, environmentalists, industrialists, bankers, financiers, c-level execs, top-level managers, professionals, consultants, analysts, investors, high networth individuals, etc.)
Cost per influencer reach: €2.485
Related accounts reached out with your PR message:
(This may also include entities, individuals, accounts, etc. associated with your press release)
London School of Hygiene & Tropical Medicine
@LSHTMpress
@london.school.hygiene.tropical.medicine

analytica laser
@analytica_laser

World Health Organization
@WHO
@WHO (FB)
+who

Rare Diseases Europe
@eurordis
@eurordis (FB)
+eurordis

Yann Le Cam
@yann_eurordis

Sarah Garner
@drsarahgarner

Harold L. Paz, MD
@drhpaz

StPancrasRenaissance
@StPancrasRen
@stpancrasren

Relevant entities, media outlets, editorial desks, journalists, bloggers, influencers, social media accounts, etc. reached out with your PR message:

UK

Prof Sally Davies
Public Health England (PHE)
Department of Health
NHS England
National Institute for Health and Care Excellence
Rare Disease UK

PharmaTimes
Pharmafocus
Pharm Exec Magazine
pharmaphorum
eyeforpharma

@CMO_England
@PHE_uk
@PublicHealthEngland
@DHgovuk
@NHSEngland
@NICEcomms
@rarediseaseuk
@RareDiseaseUK (FB)
+RarediseaseOrgUk1

@PharmaTimes
@Pharmafocus
@Pharmafocusuk
@PharmExec
@pharmaphorum
@pharmaphorum (FB)
+Pharmaphorum
@eyeforpharma
@eyeforpharma (FB)

Germany / France

PharmaNews.eu
eHealthNews.eu
EU_eHealth
Pharmaceutiques
Quotidien Pharmacien
Moniteur pharmacies
l’Ordre national des pharmaciens
Le Pharmacien de France
bionity.com (Portal für Life Sciences und Pharma)
biotechnologie.de
BIO Deutschland
EuropaBio
The European Association for Bioindustries
Pharma-Zeitung.de
Pharma Fakten

@pharmanewseu
@PharmaNewseu/110595312346047
@ehealthnews
+EhealthnewsEu
@EU_eHealth
@Pharmaceutiques
@leQPH_fr
@lequotidiendupharmacien
+LequotidiendupharmacienFr
@moniteur_news
@Ordre_Pharma
@PharmaciendeF
@LePharmaciendeFrance
@bionity_com
@bionity_de
@biotechnologie
@BIODeutschland
@EuropaBio
@EuropaBio (FB)
+113385891504870058110
@pharmazeitung
@pharmazeitung (FB)
@pharmafakten

WHO ENGAGED…
PR title views and displays, PR reads, engagements, social media insights, analytics and metrics, mentions, interactions, likes, tweets/retweets, shares, comments, replies, etc.
Total PR title views/displays:
(generic + targeted)
225,491+ people
Total PR video views:
(generic + targeted)
0 people
Cost per PR title view: €0.0022
Cost per PR video view: €0.00
PR total reads: 3,561* people read*** your press release
(Dec 1, 2017 – Dec 11, 2017 ~ 11 days**)

* The total PR reads number above is not final. It only covers the observed period for the PR distribution report, which is the active period of your PR campaign, which on itself depends on the PR distribution budget employed. The total number of people who will read your press release is highly likely to increase over time as your press release matures online and becomes more visible in the search engines, the blogoshpere and the social media space as well. Frequent updates are however only done during the active period of your PR distribution campaign, which is correlated to the PR distribution budget you’ve chosen and may be anything between one week and 30+ days with larger PR distribution budgets used. Further updates on this PR distribution report beyond the PR campaign period may be done on an irregular basis. If such an update is made on your PR distribution report in the future, EuropaWire will send a notification on the email address associated with this account.

** The observed period for the PR distribution report is tied up with the PR distribution budget used and covers the active period of your PR distribution campaign. The larger the PR distribution budget the longer both the PR distribution campaign and the observed period covered by your PR distribution report.

*** Read definition: For the sake of the metrics the read is considered and only counted as such, if the following conditions are met: 1) The press release page has fully been loaded in the browser and the time spent on the page by the visitor is at least 30 seconds; 2) An IP address is only counted once per 24 hours regardless how many times the same IP returned on the press release content; 3) Press release content viewed on social media sites do count as reads if and only when there are clear engagements (e.g. likes/loves, shares, tweets, re-tweets, etc.) reported by the respective social media accounts’ metrics and we have an access to and control over those accounts the event/engagement happened on in order to confirm/vitrify; 4) PR title viewed as well as PR title + excerpts viewed, either on the site or on social media accounts and third party sites and places, do NOT count as reads for the purpose of this report; 5) In general and by default press release reads are always more than what we can duly report in our press release distribution reports as we CANNOT gather data for press release content views, reads, shares, mentions, references, etc., on third party sites, social media accounts, private emails and communications (messengers, etc.) that are beyond our control and we have no access to their analytics and metrics; 6) Press release title and content, either partly or in its entirety, displayed, or served to viewers in the form of impressions, either on site, on third party sites or on social media, are not included in the metrics of this report as qualified reads, as we cannot tell how many of those displays/impressions can really be considered as qualified reads (e.g. no reliable data on how long the viewer engaged with the PR content AND/OR not sure whether the viewer was actually interested in what was displayed to her/him). However, it is realistic to assume certain amount of those displays and impressions can also be considered as qualified reads for the metrics of this report. We however, cannot report how many of them qualify as real reads of the press release, hence, do not have them included in this report; 7) And in general all views and reads, having occurred on sites, places and accounts we were not made aware of upon the closure of this PR distribution report are NOT counted and included in as reads; 8) Bots, in any form, type and shape, are by default excluded from the metrics of this report, whenever detected, known and possible.
In Germany (EU):
–Targeted PR title views/displays: 44,341+
–Targeted reads: 96 targeted people read your press release (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
–Cost per PR targeted read: €1.031
–PR title views / PR reads ratio: 0.21%
In France (EU):
–Targeted PR title views/displays: 31,101+
–Targeted reads: 98 targeted people read your press release (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
–Cost per PR targeted read: €1.010
–PR title views / PR reads ratio: 0.31%
In United Kingdom (EU):
–Targeted PR title views/displays: 122,759+
–Targeted reads: 265 targeted people read your press release (Dec 1, 2017 – Dec 11, 2017 ~ 11 days)
–Cost per PR targeted read: €1.12
–PR title views / PR reads ratio: 0.21%
Overall cost per PR read: €0.13
Overall PR title views / PR reads ratio: 1.57%
Who read*** your press release: 3,561 of which 459**** precisely targeted individuals living/residing in Germany (EU), France (EU), United Kingdom (EU) that speak/read English and are interested in and like Healthcare, Pharma & Biotech, Science, Government, Non Profit, Society, biopharmaceutical, pharmaceutical, high-value medicines, drug policy, medicine access, healthcare, life-saving drugs, medicine accessibility, health systems, drug developers, rare disease, etc.



*** Read definition: For the sake of the metrics the read is considered and only counted as such, if the following conditions are met: 1) The press release page has fully been loaded in the browser and the time spent on the page by the visitor is at least 30 seconds; 2) An IP address is only counted once per 24 hours regardless how many times the same IP returned on the press release content; 3) Press release content viewed on social media sites do count as reads if and only when there are clear engagements (e.g. likes/loves, shares, tweets, re-tweets, etc.) reported by the respective social media accounts’ metrics and we have an access to and control over those accounts the event/engagement happened on in order to confirm/vitrify; 4) PR title viewed as well as PR title + excerpts viewed, either on the site or on social media accounts and third party sites and places, do NOT count as reads for the purpose of this report; 5) In general and by default press release reads are always more than what we can duly report in our press release distribution reports as we CANNOT gather data for press release content views, reads, shares, mentions, references, etc., on third party sites, social media accounts, private emails and communications (messengers, etc.) that are beyond our control and we have no access to their analytics and metrics; 6) Press release title and content, either partly or in its entirety, displayed, or served to viewers in the form of impressions, either on site, on third party sites or on social media, are not included in the metrics of this report as qualified reads, as we cannot tell how many of those displays/impressions can really be considered as qualified reads (e.g. no reliable data on how long the viewer engaged with the PR content AND/OR not sure whether the viewer was actually interested in what was displayed to her/him). However, it is realistic to assume certain amount of those displays and impressions can also be considered as qualified reads for the metrics of this report. We however, cannot report how many of them qualify as real reads of the press release, hence, do not have them included in this report; 7) And in general all views and reads, having occurred on sites, places and accounts we were not made aware of upon the closure of this PR distribution report are NOT counted and included in as reads; 8) Bots, in any form, type and shape, are by default excluded from the metrics of this report, whenever detected, known and possible.



**** The difference between the number of total reads and the number of the precisely targeted individuals who read the press release as reported above is the number of people who have actually been confirmed to have read your press release, according to our measurement tools and methods, but were not verified/confirmed/identified as targeted ones through out our channels, accounts and analytics (e.g. readers coming from countries/markets outside the ones included in the PR distribution campaign’s targeting preferences; readers generally classified as generic ones; readers who have read the press release via proxy services, among others).

PR shares: 3
PR likes: 3
PR G+: 3
PR LinkedIn: 0
PR tweets/re-tweets/likes: 64
PR Pinterest: 100
PR Flipboard: 5
PR reactions / comments:
EuropaWire, Search engines, news, Blogosphere, social media, etc.
2

* Please note that PR reactions and comments may happen way beyond the initial active PR distribution campaign period, which is covered by the current PR distribution report and such PR reactions and comments, if any, may be included in future updates on this PR distribution report.
PR mentions:
Third party mentions online as a result of your press release on EuropaWire.
2

* Please note that PR mentions may happen way beyond the initial active PR distribution campaign period, which is covered by the current PR distribution report and such PR mentions, if any, may be included in future updates on this PR distribution report.
INSIGHTS…
PR insights, analyses, rates, averages, conclusions, etc.
Budget vs. target:
Reads vs. target:
Engagement vs. target:
Reach vs. budget:
Reads vs. budget:
Engagement vs. budget:
Reads vs. reach:
Engagement vs. reads:
Engagement vs. reach:
Language vs. target:
Reads vs. language:
Engagement vs. language:
Title vs. audience:
Title vs. target:
Reads vs. title:
EXTEND…
Extend PR distribution campaing to increase reach and engagement, etc.
Extend PR campaign & reach: Based on the PR distribution budget you choose from below, we’ll extend your existing PR distribution campaign for the same press release by using the same settings, preferences, targeting options, etc. The larger the PR distribution budget the longer both the PR distribution campaign and the observed period covered by your PR distribution report.



-END-
GENERAL NOTES:

Should you have any questions about this report, please contact us at info@europawire.eu.Many of the figures, numbers and values included in the PR distribution report above are not final. The current PR distribution report only covers the active period of your PR distribution campaign, which on itself depends on the PR distribution budget employed. Many of the numbers above are highly likely to increase and change over time as your press release matures online and becomes more visible in the search engines, the blogoshpere and the social media space as well. Frequent updates are however only done during the active period of your PR distribution campaign, which is correlated to the PR distribution budget you’ve chosen and may be anything between one week and 30+ days with larger PR distribution budgets used. Further updates on this PR distribution report beyond the PR campaign period may be done on an irregular basis. If such an update is made on your PR distribution report in the future, EuropaWire will send a notification on the email address associated with this account.

Please note that while this PR distribution report is not behind secure page, it is not publicly accessible and unless you give the URL (the web address) away for other people to see it, there is no other way for somebody else to find it out on the Web. No sensitive, private or financial information, if ever made available to us, will ever be published in this report section.

The information in this PR distribution report was factually accurate on the date of its last update (date shown above). This PR distribution report remains on EuropaWire website for historical purposes only. EuropaWire assumes no duty to update the information to reflect subsequent developments beyond the period of the active PR distribution campaign. Readers should not rely upon the information in this PR distribution report as current or accurate after date it was last updated on.

To have an easy and quick access to this report page for further references, please consider bookmarking it.

Thank you for releasing via EuropaWire.

Editorial Staff
EuropaWire